News

At the panel review, the members voted six to two in favor of recommending to the FDA that Kynapid be approved. An action further to the FDA review

The STAR (safety, tolerability and efficacy results of AVP-923 in pseudobulbar affect or PBA) trial will compare active treatment with Zenvia 30/10mg (dextromethorphan/quinidine or DM/Q) and Zenvia 20/10mg

Galapagos will receive total upfront fees of up to E3.5 million from GlaxoSmithKline (GSK), depending on the total number of programs within the collaboration. Galapagos could be eligible

The study is part of a larger clinical program examining the use of Interleukin-21 (IL-21) both as a single agent and in combination with approved cancer therapeutics. The

In addition, ENMD-981693 exhibited antiangiogenic activity in animal models by both inducing regression of formed blood vessels and preventing the formation of new blood vessels at well-tolerated doses.

This collaboration is expected to leverage GE Healthcare’s bioprocess solutions and design expertise and Novavax’s virus-like particle (VLP) and manufacturing platform. Novavax’s VLP-based H5N1 pandemic flu vaccine is

The license is expected to enhance Invitrogen’s growing portfolio of intellectual property surrounding click chemistry, originally developed by Nobel Laureate Barry Sharpless’s laboratory at The Scripps Research Institute

ATryn is GTC’s recombinant form of human antithrombin, a protein with anticoagulant and anti-inflammatory properties that is normally present in human plasma. Orphan drug designation provides GTC with

Two central experiments were undertaken; firstly human acute myeloid leukemia (AML) stem cells were treated with the drug, 7G3, and then injected into the mice, which were compared